Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel Irwin

Showing results (141-150 of 161) with videos related to

Pageof 17
Sort By:
European Journal of Pharmacology|June 19, 2007
Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1Nicola A Duffy, Brian D Green, Nigel Irwin, et al.
Archives of Biochemistry and Biophysics|April 13, 2007
Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonistsVictor A Gault, Kerry Hunter, Nigel Irwin, et al.
Biological Chemistry|January 31, 2007
Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) miceJeremy C Parker, Nigel Irwin, Kerry S Lavery, et al.
Biochemical Pharmacology|May 16, 2026
A novel bifunctional peptide predicted to target neuropeptide Y4 and GLP-1 receptors alleviates cognitive deficits in 5 × FAD mice by modulating cGAS-STING-mediated neuroinflammationYijie Feng, Caili Zhang, Yinuo Wei, et al.
Journal of Medicinal Chemistry|February 3, 2006
GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potentialNigel Irwin, Finbarr P M O'Harte, Victor A Gault, et al.
Biochemical Pharmacology|July 25, 2006
Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptideNigel Irwin, Gillian C Clarke, Brian D Green, et al.
Biological Chemistry|October 21, 2004
Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in miceNigel Irwin, Victor A Gault, Brian D Green, et al.
Journal of Medicinal Chemistry|February 18, 2005
Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptideNigel Irwin, Brian D Green, Victor A Gault, et al.
Biological Chemistry|October 7, 2005
Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37)Nigel Irwin, Victor A Gault, Brian D Green, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 2, 2006
Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) miceBrian D Green, Kerry S Lavery, Nigel Irwin, et al.
Pageof 17

Showing results (141-150 of 161) with videos related to

Sort By:
Pageof 17
European Journal of Pharmacology|June 19, 2007
Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1Nicola A Duffy, Brian D Green, Nigel Irwin, et al.
Archives of Biochemistry and Biophysics|April 13, 2007
Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonistsVictor A Gault, Kerry Hunter, Nigel Irwin, et al.
Biological Chemistry|January 31, 2007
Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) miceJeremy C Parker, Nigel Irwin, Kerry S Lavery, et al.
Biochemical Pharmacology|May 16, 2026
A novel bifunctional peptide predicted to target neuropeptide Y4 and GLP-1 receptors alleviates cognitive deficits in 5 × FAD mice by modulating cGAS-STING-mediated neuroinflammationYijie Feng, Caili Zhang, Yinuo Wei, et al.
Journal of Medicinal Chemistry|February 3, 2006
GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potentialNigel Irwin, Finbarr P M O'Harte, Victor A Gault, et al.
Biochemical Pharmacology|July 25, 2006
Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptideNigel Irwin, Gillian C Clarke, Brian D Green, et al.
Biological Chemistry|October 21, 2004
Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in miceNigel Irwin, Victor A Gault, Brian D Green, et al.
Journal of Medicinal Chemistry|February 18, 2005
Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptideNigel Irwin, Brian D Green, Victor A Gault, et al.
Biological Chemistry|October 7, 2005
Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37)Nigel Irwin, Victor A Gault, Brian D Green, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 2, 2006
Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) miceBrian D Green, Kerry S Lavery, Nigel Irwin, et al.
Pageof 17